2-(4,5-dichloro-6-oxopyridazin-1(6H)-yl)-N-(4-isopropylphenethyl)acetamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-(4,5-dichloro-6-oxopyridazin-1(6H)-yl)-N-(4-isopropylphenethyl)acetamide
• 英文别名: 2-(4,5-dichloro-6-oxopyridazin-1-yl)-N-[2-(4-propan-2-ylphenyl)ethyl]acetamide
• 化学式: C₁₇H₁₉Cl₂N₃O₂
• 分子量: 368.263
• InChiKey: SSDOZFYEEGHSSV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  61.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-(4-异丙基苯基)乙胺 、 Methyl 2-(4,5-dichloro-6-oxopyridazin-1(6H)-yl)acetate 在 三甲基铝 作用下， 以 甲苯 为溶剂， 以37 %的产率得到2-(4,5-dichloro-6-oxopyridazin-1(6H)-yl)-N-(4-isopropylphenethyl)acetamide
  参考文献：
  名称：

  WO2022/258992

  摘要：

  公开号：

文献信息

• [EN] PYRIDAZINONES FOR THE TREATMENT OR PREVENTION OF HYPERTENSION<br/>[FR] PYRIDAZINONES POUR LE TRAITEMENT OU LA PRÉVENTION DE L'HYPERTENSION
  申请人：[en]UNIVERSITETET I OSLO

  公开号：WO2022258992A1

  公开（公告）日：2022-12-15

  The invention provides compounds of formula (I), stereoisomers, and pharmaceutically acceptable salts thereof for use in the treatment or prevention of hypertension: wherein: R1 and R2 are independently selected from H, halogen, C1-6alkyl, C1-6haloalkyl, and -CN, provided that at least one of R1and R2is other than H; and R3is a group of the formula: wherein: n is 0 or 1; R4is H or C1-3alkyl; L1is a linking group selected from a bond, -(CH2)P- in which p is an integer from 1 to 3, and C3-6cycloalkylene; and X is selected from: (i) an aryl group optionally substituted by one or more substituents selected from C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, halogen, and -CN; (ii) a 5 or 6- membered heterocyclic ring optionally substituted by one or more substituents selected from C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, halogen, and optionally substituted phenyl; and (iii) a cycloalkyl group optionally substituted by one or more substituents selected from C1-3alkyl, C1-3haloalkyl, and halogen.
• WO2022/258992
  申请人：——

  公开号：——

  公开（公告）日：——